AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart Devices

Recruitingn/aAges 18 Years - anyAllHeinrich-Heine University, Duesseldorf
💬

In plain words

What the trial is, and whether it could suit you

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune disease that affects the peripheral nerves. It causes progressive weakness and sensory loss in the arms and legs, which can severely limit daily activities. Many patients need long-term treatment with immunoglobulins, either through intravenous infusions (IVIG) or subcutaneous injections (fSCIG). The S.T.E.P.S. study aims to explore how digital health technologies-specifically smartwatches-can help monitor the disease course and treatment effects in CIDP patients who use fSCIG at home. Current clinical tests are useful but sometimes miss small changes in strength or function. Wearables may provide a more detailed and continuous picture of patients' health between clinic visits. Study Goals: The main goal is to find out whether smartwatch data (such as step count and physical activity) reflect disease severit

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Diagnosed typical or possible typical CIDP according to the 2021 EAN/PNS criteria * Age ≥18 years * Ability to use a smartwatch as decided by the investigator * switched from IVIG to fSCIG within the prior 6 months or plan to switch during study recruitment phase * on investigator-confirmed stable IVIG therapy pre-switch Exclusion Criteria: * Age \< 18 years * Inability to operate smartwatch or smartphone device * current pregnancy and breastfeeding status * CIDP variants according to the 2021 EAN/PNS criteria
💊

What it tests

  • Not listed
📍

Where

2 sites
University Hospital Düsseldorf
Düsseldorf, Germany
University Hospital Münster
Münster, Germany
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy